Integrated Filing — IndAS



General information about company

Scrip Code 544647
NSE Symbol NEPHROPLUS
MSEI Symbol NOTLISTED
ISIN INE428V01029
Name of company Nephrocare Health Services Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 19-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 04-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Healthcare services
Start date and time of board meeting 19-05-2026   16:00:00
End date and time of board meeting 19-05-2026   17:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 26,561.50 99,884.50
Other income 1,156.90 2,451.30
Total income 27,718.40 1,02,335.80
2 Expenses
(a) Cost of materials consumed 5,963.00 22,678.90
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 4,592.80 17,178.90
(e) Finance costs 318.00 6,024.20
(f) Depreciation, depletion and amortisation expense 2,584.50 9,066.70
(f) Other Expenses
1 Healthcare professional fees 2,929.70 11,215.90
2 Hospital fees 2,123.00 7,998.50
3 Other expenses 5,576.20 18,116.00
Total other expenses 10,628.90 37,330.40
Total expenses 24,087.20 92,279.10
3 Total profit before exceptional items and tax 3,631.20 10,056.70
4 Exceptional items 0.00 0.00
5 Total profit before tax 3,631.20 10,056.70
6 Tax expense
7 Current tax 878.10 3,556.00
8 Deferred tax (593.20) (1,492.60)
9 Total tax expenses 284.90 2,063.40
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 3,346.30 7,993.30
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method (309.30) (309.30)
16 Total profit (loss) for period 3,037.00 7,684.00
17 Other comprehensive income net of taxes 592.70 1,863.40
18 Total Comprehensive Income for the period 3,629.70 9,547.40
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 3,037.00 7,684.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 592.70 1,863.40
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 2,006.80 2,006.80
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 0.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.03 8.48
Diluted earnings (loss) per share from continuing operations 2.96 8.1
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.03 8.48
Diluted earnings (loss) per share from continuing and discontinued operations 2.96 8.1
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above consolidated financial results of Nephrocare Health Services Limited (the Company) and its subsidiaries (the Company and its subsidiaries together referred to as the Group) and its joint venture have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended). 2. These consolidated financial results have been reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 19 May 2026. The above results have been subjected to audit by the statutory auditors of the Company. The statutory auditors have expressed an unmodified audit opinion on these results. 3. The consolidated financial results include the results of the following entities: Holding Company Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited) Subsidiary companies Nephrocare Health Services Central Asia FE LLC Nephrocare Health Services Nepal Private Limited Nehrocare Health Services International Pte Ltd Nephro Plus Kidney Services Company Nephrocare Health Care Services, Philippines Inc. Anram Medical Group Inc. Cadiz Dialysis Hub Inc. Dialysis Asia and Patient Care Center Inc. People’s Center For Hemodialysis Care Inc. Curis Hemodialysis Clinic Inc. Mega Health Dialysis Center Inc. Universe Dialysis and Kidney Care Centre Inc. St. Margareth Dialysis and Biocare Centre Inc. Medical Experts Group and Associates Inc. Curis Cavite Renal Corporation Renal Therapy Solutions, Inc. Rizal Dialysis and Wellness Centre OPC Bioregen Hemo Center Inc. Carmona Dialysis System Inc. Infini Care Health Systems Inc. Kolff Dialysis Inc. AIZ Hemodialysis Centre Inc. Nephro Alliance Ventures Inc. Joint Venture Nephrocare Health Services Saudi Arabia Company 4. The Group is primarily engaged in business of providing dialysis and sale of related healthcare services and products which is considered to be the only reportable segment as per Ind AS 108, 'Operating Segments'. Segment Disclosure Particulars Quarter ended Year ended 31 March 2026 31 December 2025 31 March 2025 31 March 2026 31 March 2025 Segment Revenue: Revenue from operations 2,656.15 2,597.29 2,191.93 9,988.45 7,558.12 Segment Results: Profit before tax 332.19 363.60 299.23 974.74 874.37 Segment assets: Total assets 14,708.66 15,297.04 9,964.60 14,708.66 9,964.60 Segment liabilities: Total liabilities 3,543.73 4,228.24 4,123.47 3,543.73 4,123.47 Geographical segment The business of providing dialysis and sale of related healthcare services and products are managed on a worldwide basis. The geographic information analyses the Group’s revenue by the Company’s country of domicile (i.e. India) and outside India. The revenue from operations by geographical location is presented below Geographical segment Quarter ended Year ended 31 March 2026 31 December 2025 31 March 2025 31 March 2026 31 March 2025 India 1,491.96 1,478.42 1,371.66 5,813.20 5,155.02 Outside India 1,164.19 1,118.87 820.27 4,175.25 2,403.10 5. The consolidated figures for the quarter ended 31 March 2026 are the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the third quarter of the current financial year. The consolidated figures for the quarter ended 31 March 2025 are the balancing figures between the audited consolidated figures in respect of the full financial year and the unaudited management accounts year to date consolidated figures up to the third quarter of the previous financial year. 6. During the year ended 31 March 2026, the Company has completed an initial public offering (IPO) of 18,943,020 equity shares with a face value of INR 2 each at an issue price of INR 460 per share, comprising fresh issue of 7,689,918 shares and an offer for sale of 11,253,102 shares. The Company’s equity shares were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 17 December 2025. The utilisation of net IPO proceeds is summarised below: Objectives (INR millions) Amount to be utilised as per prospectus Utilisation up to 31 March 2026 Unutilised as on 31 March 2026 Capital expenditure by our Company for opening new dialysis clinics in India 1,291.06 37.22 1,253.84 Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by our Company 1,359.99 1,359.99 - General corporate purposes 600.48 218.69 381.79 Total 3,251.53 1,615.90 1,635.63 7. During the year ended 31 March 2026, the Company incurred interest expense on financial liabilities measured at fair value through profit or loss (FVTPL) aggregating to Rs.371.89 million. The said item is non-cash and non-recurring nature and the impact has been presented under “Finance costs” in the Statement of Consolidated Financial Results. 8. The results for quarter and year ended 31 March 2026, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: nseindia.com) and on the Company's website (URL: https://nephroplus.com/investors).



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 39,619.40
Capital work-in-progress 553.80
Investment property 0.00
Goodwill 8,669.30
Other intangible assets 3,363.00
Intangible assets under development 23.70
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 714.30
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other non-current financial assets 4,808.60
Total of other non-current financial assets 4,808.60
Total non-current financial assets 5,522.90
Deferred tax assets (net) 3,396.10
Other non-current assets
1 Other non-current assets 2,021.60
Total of other non-current assets 2,021.60
Total non-current assets 63,169.80
2 Current assets
Inventories 3,303.70
Current financial asset
Current investments 17,064.10
Trade receivables, current 31,689.10
Cash and cash equivalents 12,388.90
Bank balance other than cash and cash equivalents 13,157.30
Loans, current 0.00
Other current financial assets
Total of other current financial assets 3,182.80
Total current financial assets 77,482.20
Current tax assets (net) 0.00
Other current assets
1 Other current assets 3,130.90
Total of other current assets 3,130.90
Total current assets 83,916.80
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 1,47,086.60
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 2,006.80
Other equity 1,09,642.50
Total equity attributable to owners of parent 1,11,649.30
Non controlling interest 0.00
Total equity 1,11,649.30
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 4,512.30
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 43.40
Total of other non-current financial liabilities 43.40
Total non-current financial liabilities 4,555.70
Provisions, non-current 585.70
Deferred tax liabilities (net) 354.80
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 0.00
Total of other non-current liabilities 0.00
Total non-current liabilities 5,496.20
Current liabilities
Current financial liabilities
Borrowings, current 3,458.40
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,563.50
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 12,737.20
Total Trade payable 14,300.70
Other current financial liabilities
1 Other current financial liabilities 9,669.50
Total of other current financial liabilities 9,669.50
Total current financial liabilities 27,428.60
Other current liabilities 603.60
1 Other current liabilities 603.60
Total of other current liabilities 603.60
Provisions, current 243.70
Current tax liabilities (Net) 1,665.20
Deferred government grants, Current 0.00
Total current liabilities 29,941.10
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 35,437.30
Total equity and liabilites 1,47,086.60
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement gains/(loss) on defined benefit plans 10.80 6.70
2 Income tax relating to items that will not be reclassified to profit or loss (2.70) (1.70)
Total Amount of items that will not be reclassified to profit and loss 8.10 5.00
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
1 Exchange differences on translating financial statements of foreign operations 584.60 1,858.40
Total Amount of items that will be reclassified to profit and loss 584.60 1,858.40
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 592.70 1,863.40



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 10,056.70
Adjustments for reconcile profit (loss)
Adjustments for finance costs 6,024.20
Adjustments for decrease (increase) in inventories (549.30)
Adjustments for decrease (increase) in trade receivables, current (6,879.40)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (1,295.40)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (81.20)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 3,280.70
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 94.50
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 9,066.70
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 207.40
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 4,658.60
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 945.70
Adjustments for share-based payments 918.30
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 1,449.50
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 15,948.90
Net cash flows from (used in) operations 26,005.60
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 2,747.70
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 23,257.90
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 54.70
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 5,039.90
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 418.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 22.20
Purchase of property, plant and equipment 11,893.60
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 42.60
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 799.10
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (24,525.40)
Net cash flows from (used in) investing activities (41,043.50)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 39,020.50
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 20,279.30
Payments of lease liabilities 1,182.50
Dividends paid 0.00
Interest paid 1,847.80
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 15,710.90
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (2,074.70)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 1,881.90
Net increase (decrease) in cash and cash equivalents (192.80)
Cash and cash equivalents cash flow statement at beginning of period 12,581.70
Cash and cash equivalents cash flow statement at end of period 12,388.90





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s. BSR and Co., Chartered Accountants Yes 30-04-2029